News Agency
The Times

SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis

  • Written by Media Outreach
HONG KONG SAR - Media OutReach - 26 April 2023 - A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce that Phase III...

Read more: SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab)...

Shotcrete Concrete: How Professional Application Supports Strong Construction

Shotcrete is a method of placing concrete by spraying it at high velocity onto a prepared surface. Shotcrete concrete can be used in projects where access, geometry or site conditions make conventional placement less practical, provided the design and application... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion